Restricted access

Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer based on clinical evidence and expert consensus. NCCN Panel guidance on treatment decisions for patients with localized disease is represented in this version. Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations. The full version of these guidelines, including treatment of patients with advanced disease, can be found online at the NCCN website.

  • 1.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:929.

  • 2.

    Social Security Administration. Period Life Table. 2009. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed March 10, 2014.

    • Search Google Scholar
    • Export Citation
  • 3.

    Howard DH. Life expectancy and the value of early detection. J Health Econ 2005;24:891906.

  • 4.

    D’Amico AV, Whittington R, Malkowicz SB. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168172.

    • Search Google Scholar
    • Export Citation
  • 5.

    D’Amico AV, Whittington R, Malkowicz SB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281286.

    • Search Google Scholar
    • Export Citation
  • 6.

    D’Amico AV, Whittington R, Malkowicz SB. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969974.

    • Search Google Scholar
    • Export Citation
  • 7.

    Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 2012;80:10751079.

    • Search Google Scholar
    • Export Citation
  • 8.

    Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed March 24, 2014.

  • 9.

    Makarov DV, Trock BJ, Humphreys EB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:10951101.

    • Search Google Scholar
    • Export Citation
  • 10.

    Kattan MW, Eastham JA, Wheeler TM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:17921797.

    • Search Google Scholar
    • Export Citation
  • 11.

    Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed March 24, 2014.

    • Search Google Scholar
    • Export Citation
  • 12.

    Stephenson AJ, Scardino PT, Eastham JA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715717.

    • Search Google Scholar
    • Export Citation
  • 13.

    Stephenson AJ, Kattan MW, Eastham JA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:43004305.

    • Search Google Scholar
    • Export Citation
  • 14.

    Graefen M, Haese A, Pichlmeier U. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857863.

    • Search Google Scholar
    • Export Citation
  • 15.

    Ohori M, Kattan MW, Koh H. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:18441849; discussion 1849.

    • Search Google Scholar
    • Export Citation
  • 16.

    Steuber T, Graefen M, Haese A. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939944; discussion 944.

    • Search Google Scholar
    • Export Citation
  • 17.

    Briganti A, Chun FK, Salonia A. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007;51:112119; discussion 119-120.

    • Search Google Scholar
    • Export Citation
  • 18.

    Kattan MW, Potters L, Blasko JC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393399.

    • Search Google Scholar
    • Export Citation
  • 19.

    Potters L, Morgenstern C, Calugaru E. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179:S2024.

    • Search Google Scholar
    • Export Citation
  • 20.

    Zelefsky MJ, Kattan MW, Fearn P. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283287.

    • Search Google Scholar
    • Export Citation
  • 21.

    Jeldres C, Suardi N, Walz J. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:13061313.

    • Search Google Scholar
    • Export Citation
  • 22.

    Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801808.

    • Search Google Scholar
    • Export Citation
  • 23.

    Stephenson AJ, Scardino PT, Kattan MW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:20352041.

    • Search Google Scholar
    • Export Citation
  • 24.

    Dearnaley DP, Khoo VS, Norman AR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267272.

    • Search Google Scholar
    • Export Citation
  • 25.

    Khoo VS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 2005;17:560571.

    • Search Google Scholar
    • Export Citation
  • 26.

    D’Amico AV, Cote K, Loffredo M. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:45674573.

    • Search Google Scholar
    • Export Citation
  • 27.

    D’Amico AV, Moul JW, Carroll PR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:13761383.

    • Search Google Scholar
    • Export Citation
  • 28.

    Johansson JE, Holmberg L, Johansson S. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467471.

    • Search Google Scholar
    • Export Citation
  • 29.

    van den Bergh RC, Essink-Bot ML, Roobol MJ. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009;115:38683878.

    • Search Google Scholar
    • Export Citation
  • 30.

    Sakr WA, Grignon DJ, Crissman JD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439443.

    • Search Google Scholar
    • Export Citation
  • 31.

    Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:22392246.

    • Search Google Scholar
    • Export Citation
  • 32.

    Schroder FH, Hugosson J, Roobol MJ. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981990.

  • 33.

    Schroder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:13201328.

  • 34.

    Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:81658169.

  • 35.

    Andriole GL, Crawford ED, Grubb RL 3rd. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:13101319.

  • 36.

    Andriole GL, Bostwick DG, Brawley OW. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:11921202.

  • 37.

    Andriole GL, Crawford ED, Grubb RL 3rd. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125132.

    • Search Google Scholar
    • Export Citation
  • 38.

    Sandblom G, Varenhorst E, Rosell J. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539.

  • 39.

    Hugosson J, Carlsson S, Aus G. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725732.

    • Search Google Scholar
    • Export Citation
  • 40.

    Miller DC, Gruber SB, Hollenbeck BK. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:11341141.

    • Search Google Scholar
    • Export Citation
  • 41.

    Draisma G, Etzioni R, Tsodikov A. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374383.

    • Search Google Scholar
    • Export Citation
  • 42.

    Draisma G, Boer R, Otto SJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868878.

    • Search Google Scholar
    • Export Citation
  • 43.

    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368374.

    • Search Google Scholar
    • Export Citation
  • 44.

    Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101:20012005.

    • Search Google Scholar
    • Export Citation
  • 45.

    Chun FK, Haese A, Ahyai SA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701709.

    • Search Google Scholar
    • Export Citation
  • 46.

    Bastian PJ, Carter BH, Bjartell A. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:13211330.

    • Search Google Scholar
    • Export Citation
  • 47.

    Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009;301:21412151.

  • 48.

    Sundi D, Ross AE, Humphreys EB. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 2013;31:29912997.

    • Search Google Scholar
    • Export Citation
  • 49.

    Carter HB, Kettermann A, Warlick C. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:23592364; discussion 2364-2355.

    • Search Google Scholar
    • Export Citation
  • 50.

    Dall’Era MA, Konety BR, Cowan JE. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:26642670.

    • Search Google Scholar
    • Export Citation
  • 51.

    Klotz L, Zhang L, Lam A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126131.

    • Search Google Scholar
    • Export Citation
  • 52.

    Sheridan TB, Carter HB, Wang W. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008;179:901904; discussion 904-905.

    • Search Google Scholar
    • Export Citation
  • 53.

    Tosoian JJ, Trock BJ, Landis P. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:21852190.

    • Search Google Scholar
    • Export Citation
  • 54.

    Loblaw A, Zhang L, Lam A. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol 2010;184:19421946.

    • Search Google Scholar
    • Export Citation
  • 55.

    Ross AE, Loeb S, Landis P. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:28102816.

    • Search Google Scholar
    • Export Citation
  • 56.

    Klotz L. Point: active surveillance for favorable risk prostate cancer. J Natl Compr Canc Netw 2007;5:693698.

  • 57.

    Feliciano J, Teper E, Ferrandino M. The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952955; discussion 955.

    • Search Google Scholar
    • Export Citation
  • 58.

    Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:26642669.

    • Search Google Scholar
    • Export Citation
  • 59.

    Bill-Axelson A, Holmberg L, Ruutu M. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:17081717.

    • Search Google Scholar
    • Export Citation
  • 60.

    Pierorazio PM, Ross AE, Lin BM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int 2012;110:11221128.

    • Search Google Scholar
    • Export Citation
  • 61.

    Chade DC, Eastham J, Graefen M. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61:961971.

    • Search Google Scholar
    • Export Citation
  • 62.

    Shekarriz B, Upadhyay J, Pontes JE. Salvage radical prostatectomy. Urol Clin North Am 2001;28:545553.

  • 63.

    Klein EA, Bianco FJ, Serio AM. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008;179:22122216; discussion 2216-2217.

    • Search Google Scholar
    • Export Citation
  • 64.

    Begg CB, Riedel ER, Bach PB. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:11381144.

  • 65.

    Herrell SD, Smith JA Jr. Robotic-assisted laparoscopic prostatectomy: what is the learning curve? Urology 2005;66:105107.

  • 66.

    Smith JA Jr., Herrell SD. Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages? J Clin Oncol 2005;23:81708175.

    • Search Google Scholar
    • Export Citation
  • 67.

    Hu JC, Gu X, Lipsitz SR. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009;302:15571564.

  • 68.

    Parsons JK, Bennett JL. Outcomes of retropubic, laparoscopic, and robotic-assisted prostatectomy. Urology 2008;72:412416.

  • 69.

    Ficarra V, Novara G, Rosen RC. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405417.

    • Search Google Scholar
    • Export Citation
  • 70.

    Ficarra V, Novara G, Ahlering TE. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418430.

    • Search Google Scholar
    • Export Citation
  • 71.

    Resnick MJ, Koyama T, Fan KH. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436445.

  • 72.

    Nam RK, Cheung P, Herschorn S. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 2014;15:223231.

    • Search Google Scholar
    • Export Citation
  • 73.

    Freire MP, Weinberg AC, Lei Y. Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol 2009;56:972980.

    • Search Google Scholar
    • Export Citation
  • 74.

    Abel EJ, Masterson TA, Warner JN. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology 2009;73:13361340.

    • Search Google Scholar
    • Export Citation
  • 75.

    Davis JW, Chang DW, Chevray P. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009;55:11351143.

    • Search Google Scholar
    • Export Citation
  • 76.

    Cagiannos I, Karakiewicz P, Eastham JA. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:17981803.

    • Search Google Scholar
    • Export Citation
  • 77.

    Briganti A, Blute ML, Eastham JH. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55:12511265.

  • 78.

    Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007;52:2937.

    • Search Google Scholar
    • Export Citation
  • 79.

    Masterson TA, Bianco FJ Jr., Vickers AJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:13201324; discussion 1324-1325.

    • Search Google Scholar
    • Export Citation
  • 80.

    Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121125.

    • Search Google Scholar
    • Export Citation
  • 81.

    Allaf ME, Palapattu GS, Trock BJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:18401844.

    • Search Google Scholar
    • Export Citation
  • 82.

    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849854.

    • Search Google Scholar
    • Export Citation
  • 83.

    Daneshmand S, Quek ML, Stein JP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:22522255.

    • Search Google Scholar
    • Export Citation
  • 84.

    Wagner M, Sokoloff M, Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer—therapeutic? J Urol 2008;179:408413.

  • 85.

    Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:5159.

    • Search Google Scholar
    • Export Citation
  • 86.

    Koper PC, Stroom JC, van Putten WL. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727734.

    • Search Google Scholar
    • Export Citation
  • 87.

    Michalski JM, Bae K, Roach M. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010;76:1422.

    • Search Google Scholar
    • Export Citation
  • 88.

    Jacobs BL, Zhang Y, Schroeck FR. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA 2013;309:25872595.

    • Search Google Scholar
    • Export Citation
  • 89.

    Zelefsky MJ, Levin EJ, Hunt M. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:11241129.

    • Search Google Scholar
    • Export Citation
  • 90.

    Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007;10:8286.

    • Search Google Scholar
    • Export Citation
  • 91.

    Jacobs BL, Zhang Y, Skolarus TA. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol 2014;65:162168.

    • Search Google Scholar
    • Export Citation
  • 92.

    Peeters ST, Heemsbergen WD, Koper PC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:19901996.

    • Search Google Scholar
    • Export Citation
  • 93.

    Pollack A, Zagars GK, Starkschall G. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:10971105.

    • Search Google Scholar
    • Export Citation
  • 94.

    Zietman AL, DeSilvio ML, Slater JD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:12331239.

    • Search Google Scholar
    • Export Citation
  • 95.

    Kuban DA, Tucker SL, Dong L. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:6774.

    • Search Google Scholar
    • Export Citation
  • 96.

    Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol 2011;34:1115.

  • 97.

    Eade TN, Hanlon AL, Horwitz EM. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68:682689.

    • Search Google Scholar
    • Export Citation
  • 98.

    Pollack A, Walker G, Horwitz EM. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013;31:38603868.

    • Search Google Scholar
    • Export Citation
  • 99.

    Arcangeli S, Strigari L, Gomellini S. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:11721178.

    • Search Google Scholar
    • Export Citation
  • 100.

    Potosky AL, Davis WW, Hoffman RM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:13581367.

    • Search Google Scholar
    • Export Citation
  • 101.

    Sanda MG, Dunn RL, Michalski J. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:12501261.

    • Search Google Scholar
    • Export Citation
  • 102.

    Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:14171428.

    • Search Google Scholar
    • Export Citation
  • 103.

    Critz FA, Benton JB, Shrake P, Merlin ML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol 2013;189:878883.

    • Search Google Scholar
    • Export Citation
  • 104.

    Bolla M, Van Tienhoven G, Warde P. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:10661073.

    • Search Google Scholar
    • Export Citation
  • 105.

    Pilepich MV, Winter K, Lawton CA. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:12851290.

    • Search Google Scholar
    • Export Citation
  • 106.

    Warde P, Mason M, Ding K. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:21042111.

    • Search Google Scholar
    • Export Citation
  • 107.

    Widmark A, Klepp O, Solberg A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301308.

    • Search Google Scholar
    • Export Citation
  • 108.

    Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 2007;19:289301.

    • Search Google Scholar
    • Export Citation
  • 109.

    Buyyounouski MK, Price RA Jr., Harris EE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010;76:12971304.

    • Search Google Scholar
    • Export Citation
  • 110.

    Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011;6:3.

  • 111.

    Kang JK, Cho CK, Choi CW. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011;97:4348.

  • 112.

    Madsen BL, Hsi RA, Pham HT. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:10991105.

    • Search Google Scholar
    • Export Citation
  • 113.

    Chen LN, Suy S, Uhm S. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013;8:58.

    • Search Google Scholar
    • Export Citation
  • 114.

    Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.

    • Search Google Scholar
    • Export Citation
  • 115.

    King CR, Freeman D, Kaplan I. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217221.

    • Search Google Scholar
    • Export Citation
  • 116.

    Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111117.

    • Search Google Scholar
    • Export Citation
  • 117.

    Masson S, Persad R, Bahl A. HDR brachytherapy in the management of high-risk prostate cancer. Adv Urol 2012;2012:980841.

  • 118.

    Merrick GS, Butler WM, Wallner KE. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64:754759.

    • Search Google Scholar
    • Export Citation
  • 119.

    Eade TN, Horwitz EM, Ruth K. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008;71:338345.

    • Search Google Scholar
    • Export Citation
  • 120.

    Wong WW, Vora SA, Schild SE. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 2009;115:55965606.

    • Search Google Scholar
    • Export Citation
  • 121.

    Lee N, Wuu CS, Brody R. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:14571460.

    • Search Google Scholar
    • Export Citation
  • 122.

    Henkel TO, Kahmann F. Permanent brachytherapy: prostate seed implants as an out-patient treatment. Arch Ital Urol Androl 2000;72:295301.

  • 123.

    Nag S, Bice W, DeWyngaert K. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221230.

    • Search Google Scholar
    • Export Citation
  • 124.

    Al-Salihi O, Mitra A, Payne H. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis 2006;9:370373.

    • Search Google Scholar
    • Export Citation
  • 125.

    Fang FM, Wang YM, Wang CJ. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol 2008;38:474479.

    • Search Google Scholar
    • Export Citation
  • 126.

    Pieters BR, van de Kamer JB, van Herten YR. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008;88:4652.

    • Search Google Scholar
    • Export Citation
  • 127.

    Soumarova R, Homola L, Perkova H, Stursa M. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori 2007;93:3744.

    • Search Google Scholar
    • Export Citation
  • 128.

    Sathya JR, Davis IR, Julian JA. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:11921199.

    • Search Google Scholar
    • Export Citation
  • 129.

    Hoskin PJ, Motohashi K, Bownes P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007;84:114120.

    • Search Google Scholar
    • Export Citation
  • 130.

    Hoskin PJ, Rojas AM, Bownes PJ. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012;103:217222.

    • Search Google Scholar
    • Export Citation
  • 131.

    Shen X, Keith SW, Mishra MV. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012;83:11541159.

    • Search Google Scholar
    • Export Citation
  • 132.

    Bittner N, Merrick GS, Butler WM. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 2012;11:250255.

    • Search Google Scholar
    • Export Citation
  • 133.

    Martinez-Monge R, Moreno M, Ciervide R. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 2012;82:e469476.

    • Search Google Scholar
    • Export Citation
  • 134.

    D’Amico AV, Moran BJ, Braccioforte MH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:39233928.

    • Search Google Scholar
    • Export Citation
  • 135.

    Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009;32:342347.

    • Search Google Scholar
    • Export Citation
  • 136.

    Dattoli M, Wallner K, True L. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol 2010;2010:471375.

    • Search Google Scholar
    • Export Citation
  • 137.

    Hoskin P. High dose rate brachytherapy for prostate cancer. Cancer Radiother 2008;12:512514.

  • 138.

    Grills IS, Martinez AA, Hollander M. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171:10981104.

    • Search Google Scholar
    • Export Citation
  • 139.

    Vargas C, Ghilezan M, Hollander M. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 2005;174:882887.

    • Search Google Scholar
    • Export Citation
  • 140.

    Coen JJ, Zietman AL. Proton radiation for localized prostate cancer. Nat Rev Urol 2009;6:324330.

  • 141.

    Yu JB, Soulos PR, Herrin J. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013;105:2532.

    • Search Google Scholar
    • Export Citation
  • 142.

    Coen JJ, Paly JJ, Niemierko A. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:e201209.

    • Search Google Scholar
    • Export Citation
  • 143.

    Allen AM, Pawlicki T, Dong L. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol 2012;103:811.

    • Search Google Scholar
    • Export Citation
  • 144.

    Babaian RJ, Donnelly B, Bahn D. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008;180:19932004.

    • Search Google Scholar
    • Export Citation
  • 145.

    Bahn D, de Castro Abreu AL, Gill IS. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012;62:5563.

    • Search Google Scholar
    • Export Citation
  • 146.

    Donnelly BJ, Saliken JC, Brasher PM. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323330.

    • Search Google Scholar
    • Export Citation
  • 147.

    Robinson JW, Donnelly BJ, Siever JE. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009;115:46954704.

    • Search Google Scholar
    • Export Citation
  • 148.

    Chin JL, Al-Zahrani AA, Autran-Gomez AM. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 2012;188:11701175.

    • Search Google Scholar
    • Export Citation
  • 149.

    Barret E, Ahallal Y, Sanchez-Salas R. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013;63:618622.

  • 150.

    Lu-Yao GL, Albertsen PC, Moore DF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173181.

    • Search Google Scholar
    • Export Citation
  • 151.

    D’Amico AV, Chen MH, Renshaw AA. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289295.

    • Search Google Scholar
    • Export Citation
  • 152.

    Denham JW, Steigler A, Lamb DS. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451459.

    • Search Google Scholar
    • Export Citation
  • 153.

    Jones CU, Hunt D, McGowan DG. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107118.

  • 154.

    Roach M 3rd, Bae K, Speight J. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585591.

    • Search Google Scholar
    • Export Citation
  • 155.

    Horwitz EM, Bae K, Hanks GE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:24972504.

    • Search Google Scholar
    • Export Citation
  • 156.

    Bolla M, de Reijke TM, Van Tienhoven G. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:25162527.

    • Search Google Scholar
    • Export Citation
  • 157.

    Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009;27:21372143.

    • Search Google Scholar
    • Export Citation
  • 158.

    Kumar S, Shelley M, Harrison C. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019.

    • Search Google Scholar
    • Export Citation
  • 159.

    Messing EM, Manola J, Yao J. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472479.

    • Search Google Scholar
    • Export Citation
  • 160.

    Loblaw DA, Virgo KS, Nam R. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:15961605.

    • Search Google Scholar
    • Export Citation
  • 161.

    Wong YN, Freedland S, Egleston B. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009;27:100105.

  • 162.

    McLeod DG, Iversen P, See WA. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247254.

    • Search Google Scholar
    • Export Citation
  • 163.

    McLeod DG, See WA, Klimberg I. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006;176:7580.

    • Search Google Scholar
    • Export Citation
  • 164.

    Briganti A, Passoni N, Ferrari M. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551558.

    • Search Google Scholar
    • Export Citation
  • 165.

    Wolf JS Jr., Cher M, Dall’era M. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153:993999.

    • Search Google Scholar
    • Export Citation
  • 166.

    Dickinson L, Ahmed HU, Allen C. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59:477494.

    • Search Google Scholar
    • Export Citation
  • 167.

    Dall’Era MA, Albertsen PC, Bangma C. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976983.

    • Search Google Scholar
    • Export Citation
  • 168.

    Pound CR, Partin AW, Eisenberger MA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:15911597.

    • Search Google Scholar
    • Export Citation
  • 169.

    Thompson IM, Tangen CM, Paradelo J. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956962.

    • Search Google Scholar
    • Export Citation
  • 170.

    Thompson IM Jr., Tangen CM, Paradelo J. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:23292335.

    • Search Google Scholar
    • Export Citation
  • 171.

    Swanson GP, Goldman B, Tangen CM. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol 2008;180:24532457; discussion 2458.

    • Search Google Scholar
    • Export Citation
  • 172.

    Van der Kwast TH, Bolla M, Van Poppel H. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:41784186.

    • Search Google Scholar
    • Export Citation
  • 173.

    Wiegel T, Bottke D, Steiner U. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:29242930.

    • Search Google Scholar
    • Export Citation
  • 174.

    Da Pozzo LF, Cozzarini C, Briganti A. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009;55:10031011.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1142 856 21
PDF Downloads 182 133 1
EPUB Downloads 0 0 0